Repligen Corporation (NASDAQ:RGEN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Repligen Corporation (NASDAQ:RGEN) have received an average recommendation of “Moderate Buy” from the eighteen brokerages that are covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $168.57.

Several research analysts recently weighed in on the stock. Zacks Research cut shares of Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research note on Tuesday, July 7th. JPMorgan Chase & Co. increased their price target on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Evercore restated an “outperform” rating and set a $160.00 price objective on shares of Repligen in a research report on Monday, July 6th. Finally, Citigroup upgraded shares of Repligen to a “buy” rating in a research report on Tuesday, July 7th.

Repligen Price Performance

NASDAQ:RGEN opened at $181.70 on Tuesday. Repligen has a 52-week low of $100.99 and a 52-week high of $198.87. The stock has a fifty day moving average of $170.38 and a 200 day moving average of $141.32. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The firm has a market capitalization of $10.26 billion, a price-to-earnings ratio of 248.90, a P/E/G ratio of 3.32 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period in the prior year, the company earned $0.26 EPS. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, research analysts expect that Repligen will post 2.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Repligen

Hedge funds and other institutional investors have recently modified their holdings of the company. United Capital Financial Advisors LLC purchased a new position in shares of Repligen during the second quarter worth approximately $380,756,000. Maverick Capital Ltd. purchased a new stake in shares of Repligen in the 1st quarter valued at $178,946,000. Wasatch Advisors LP purchased a new stake in shares of Repligen in the 1st quarter valued at $146,513,000. William Blair Investment Management LLC bought a new position in shares of Repligen during the 2nd quarter valued at $107,593,000. Finally, Bamco Inc. NY bought a new position in shares of Repligen during the 2nd quarter valued at $102,121,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.